Deflazacort
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | H02AB13 (WHO) |
Pharmacokinetic data | |
Protein binding | 40% |
Metabolism | By plasma esterases, to active metabolite |
Biological half-life | 1.1–1.9 hours (metabolite) |
Excretion | Renal (70%) and fecal (30%) |
Identifiers | |
| |
CAS Number | 14484-47-0 |
PubChem (CID) | 26709 |
ChemSpider | 164861 |
UNII | KR5YZ6AE4B |
KEGG | D03671 |
ChEMBL | CHEMBL1201891 |
ECHA InfoCard | 100.034.969 |
Chemical and physical data | |
Formula | C25H31NO6 |
Molar mass | 441.517 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.
Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.[1] Its potency is around 70–90% that of prednisone.[2]
It is sold in Bangladesh as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the United Kingdom by Shire under the trade name Calcort;[2] in Brazil as Cortax, Decortil, and Deflanil; in India as MOAID, ZENFLAV BY TIGRIS, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.[3] It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. [4]
References
- ↑ Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical Research. 12 (7): 1096–100. PMID 7494809.
- 1 2 "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.
- ↑ "Substâncias: DEFLAZACORT" (in Portuguese). Centralx. 2008. Retrieved on October 28, 2008.
- ↑ http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1